3-chloro-4-fluoro-N,N-dimethylbenzamide | 871657-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-chloro-4-fluoro-N,N-dimethylbenzamide
• CAS: 871657-07-7
• 化学式: C₉H₉ClFNO
• 分子量: 201.628
• InChiKey: CFTIEERQYDTPAZ-UHFFFAOYSA-N

物化性质

• 沸点：
  319.5±32.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-chloro-4-fluoro-N,N-dimethylbenzamide 在 肼 、 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 17.0h， 生成 3-chloro-4-hydrazino-N,N-dimethyl-benzamide hydrochloride
  参考文献：
  名称：

  [EN] THIAZOLYL-DIHYDRO-INDAZOLES
  [FR] THIAZOLYLDIHYDROINDAZOLES

  摘要：

  本发明涵盖了一般式（1）中R1至R3的化合物，其中R1至R3的定义如权利要求书中所述，适用于治疗以细胞过度或异常增殖为特征的疾病，并用于制备具有上述特性的药物。

  公开号：

  WO2009112565A1
• 作为产物：
  描述：

  3-氯-4-氟苯硼酸 在 bis-triphenylphosphine-palladium(II) chloride 、 copper diacetate 、 sodium carbonate 作用下， 以 2,2,2-三氟乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.5h， 生成 3-chloro-4-fluoro-N,N-dimethylbenzamide
  参考文献：
  名称：

  硼酸和硫代亚氨酸盐KAT转移试剂催化合成酰基三氟硼酸钾（KAT）

  摘要：

  我们报道了钯催化的硼酸与硫代亚氨酸酯KAT转移试剂的交叉偶联反应，合成了酰基三氟硼酸钾（KAT）。使用催化Pd II和Cu II将广泛使用的芳基和乙烯基硼酸与市售的亚氨基磺酸1组合添加剂能够以高收率和良好的官能团耐受性制备KAT。这种将CO正式插入有机硼酸中的方法也可以使用稍加修改的方法应用于硼酸频哪醇酯和有机三氟硼酸钾。通过利用KAT及其三氟硼酸亚胺（TIM）衍生物的独特化学结构，可以将交叉偶合伸缩到酰胺和α-氨基三氟硼酸酯的一锅法合成中。

  DOI：

  10.1002/anie.202014581

文献信息

• CHEMICAL COMPOUNDS
  申请人：Campbell Leonie

  公开号：US20080171734A1

  公开（公告）日：2008-07-17

  The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R 1 , A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).

  这项发明涉及一类新型化合物，其化学式为（I）或其盐：其中R1、A和HET-1如规范中所述，可能在通过葡萄糖激酶（GLK）介导的疾病或医疗状况的治疗或预防中有用，例如2型糖尿病。该发明还涉及包括所述化合物的药物组合物，使用所述化合物治疗由GLK介导的疾病的方法，以及制备化合物（I）的方法。
• Merging Electron Transfer with 1,2‐Metalate Rearrangement: Deoxygenative Arylation of Aromatic Amides with Arylboronic Esters
  作者：Jiwen Jiao、Xiaoming Wang

  DOI：10.1002/anie.202104359

  日期：2021.7.26

  rearrangement, a wide range of aromatic amides react smoothly with arylboron reagents, affording a series of biologically relevant diarylmethylamines as deoxygenative C−C bond cross-coupling products. With its simplicity and versatility, this reaction shows great promise in the synthesis of amines from amides, which may open up new avenues in retrosynthetic planning and find widespread use in academia

  在许多类型的化学转化中，酰胺本质上是惰性的羧基衍生物。特别是，由于共振稳定的酰胺 C=O 键的惰性，酰胺与合成重要胺的脱氧 C-C 键形成对合成化学家来说是一个长期存在的挑战。本文公开了通过将电子转移诱导的活化与 1,2-金属酸盐重排相结合，广泛的芳香酰胺与芳基硼试剂顺利反应，提供一系列生物学相关的二芳基甲胺作为脱氧 C-C 键交叉偶联产品。由于其简单性和多功能性，该反应在由酰胺合成胺方面显示出巨大的希望，这可能为逆合成规划开辟新的途径，并在学术界和工业界得到广泛应用。
• Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes
  申请人：Johnstone Craig

  公开号：US20090253676A1

  公开（公告）日：2009-10-08

  Compounds of Formula (I): wherein: R 1 is hydroxymethyl; R 2 is selected from —C(O)NR 4 R 5 , —SO 2 NR 4 R 5 , —S(O) p R 4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R 3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R 4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R 5 is hydrogen or (1-4C)alkyl; or R 4 and R 5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro-drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  化学式（I）的化合物：其中：R1为羟甲基；R2选自- C（O）NR4R5，-SO2NR4R5，-S（O）pR4和HET-2; HET-1为5-或6-成员的，可选择性取代C-连接的杂芳基环；HET-2为4-，5-或6-成员的，C-或N-连接的可选择性取代杂环烷基环；R3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基；R4选自例如氢，可选择性取代的（1-4C）烷基和HET-2；R5为氢或（1-4C）烷基；或R4和R5与它们所附着的氮原子一起可以形成由HET-3定义的杂环烷基环系统；HET-3例如为可选择性取代的N-连接，4、5或6成员的，饱和或部分不饱和的杂环烷基环；p为（每次独立）0、1或2；m为0或1；n为0、1或2；但当m为0时，则n为1或2；或其盐、前药或溶剂。还描述了它们作为GLK激活剂的用途、含有它们的制药组合物以及它们的制备方法。
• Benzamide Derivatives That Act Upon The Glucokinase Enzyme
  申请人：Johnstone Craig

  公开号：US20070287693A1

  公开（公告）日：2007-12-13

  Compounds of Formula (I): wherein R 1 is hydroxymethyl; R 2 is selected from —C(O)NR 4 R 5 , SO 2 NR 4 R 5 , S(O) p R 4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted hererocyclyl ring; R 3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R 4 is selected from, for example, hydrogen, optionally substituted (1-4C)alkyl and HET-2; R 5 is hydrogen or (1-4C)alkyl; or R 4 and R 5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is, for example, an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  化合物的公式（I）：其中R1是羟甲基；R2选自—C（O）NR4R5，SO2NR4R5，S（O）pR4和HET-2；HET-1是5-或6-成员的，可选择取代的C-连接杂芳基环；HET-2是4-，5-或6-成员的，C-或N-连接的可选择取代的杂环基环；R3选自卤素，氟甲基，二氟甲基，三氟甲基，甲基，甲氧基和氰基；R4选自例如氢，可选择取代的（1-4C）烷基和HET-2；R5是氢或（1-4C）烷基；或者R4和R5与它们所连接的氮原子一起可以形成由HET-3定义的杂环基环系统；HET-3是例如可选择取代的N-连接的，4、5或6成员的，饱和或部分不饱和的杂环基环；p（独立于每次出现）为0、1或2；m为0或1；n为0、1或2；但是当m为0时，则n为1或2；还描述了它们的盐，前药或溶剂。还描述了它们作为GLK激活剂的用途，含有它们的制药组合物以及它们的制备方法。
• Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes
  申请人：Johnstone Craig

  公开号：US20080015203A1

  公开（公告）日：2008-01-17

  Compounds of Formula (I) wherein: R 1 is hydroxymethyl; R 2 is selected from —C(O)NR 4 R 5 , SO 2 NR 4 R 5 , S(O) p R 4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R 3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R 4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R 5 is hydrogen or (1-4C)alkyl; or R 4 and R 5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

  化合物的公式(I)，其中：R1为羟甲基；R2选自—C(O)NR4R5，SO2NR4R5，S(O)pR4和HET-2；HET-1为5-或6-成员的、可选地取代的C-连接杂芳基环；HET-2是4-、5-或6-成员的、可选地取代的杂环基环，可以是C-或N-连接；R3选自卤素、氟甲基、二氟甲基、三氟甲基、甲基、甲氧基和氰基；R4选自例如氢、可选地取代的(1-4C)烷基和HET-2；R5为氢或(1-4C)烷基；或者R4和R5与它们连接的氮原子一起可以形成由HET-3定义的杂环基环系统；HET-3例如为可选地取代的N-连接的、4、5或6成员的、饱和或部分不饱和的杂环基环；p是（每次独立地）0、1或2；m是0或1；n是0、1或2；但是当m为0时，n为1或2；或其盐、前药或溶剂。还描述了它们作为GLK激活剂的用途、包含它们的制药组合物以及它们的制备方法。